The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Major contract signed in the US

15 Aug 2018 07:00

RNS Number : 8155X
Premier Veterinary Group PLC
15 August 2018
 

PREMIER VETERINARY GROUP PLC

("PVG" or "the Company")

 

 

MAJOR CONTRACT SIGNED IN THE US FOR

PREMIER PET CARE PLAN

 

London, UK, 15TH August 2018 - Premier Veterinary Group plc (LSE: PVG) announces that its wholly-owned subsidiary, Premier Vet Alliance (US) Limited ("PVA"), has signed a contract with a major corporate veterinary consolidator in the US ("the Customer").

 

The Customer has over 140 hospitals across 25 States with in excess of 700 Full Time Vet Equivalents ("FTVE"). Of these hospitals in excess of 100 are companion animal, the target market for PVG, with an FTVE compliment of over 500. The average size of the Customer's hospitals is in the region of 5 FTVE which is approximately twice the average size of UK and US practices currently served by PVG.

 

The contract, initially, is to introduce PVA's preventative healthcare programme for pets, branded "Premier Pet Care Plan" ("PPCP"), to 15 of the Customer's companion animal hospitals. At the end of the pilot phase, which is expected to last between three and six months, the contract can be extended to a 3 year term with a full roll out to all of the Customer's companion animal hospitals. This contract is unlike previous co-operation agreements that have been signed with distributors in the US, and will see PPCP launched in all the Customer's existing sites over a 12 month period. Furthermore, PPCP will be launched in hospitals acquired or opened by the Customer in the future throughout the contract period. As the fourth largest corporate consolidator in the US, this represents a significant opportunity to grow PVA's existing market share in this key territory.

 

Dominic Tonner, Chief Executive Officer of PVG, added:

 

"I am delighted to announce this deal which will help propel the business forward with a large and well respected US corporate consolidator. It is clear vindication and reward for the unswerving focus the team have for the business and the changes we have implemented to satisfy the US market."

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

For further information, please contact:

 

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Will Evans, Chief Financial Officer

 

 

Note to Editors:

 

The available market for preventative healthcare programmes for pets across the US is estimated at 70 million dogs and 74 million cats (U.S. Pet Ownership & Demographics Sourcebook 2012). The largest operator in this segment in the US is reported to have one million pets on such programmes.

 

PVG's services to third party veterinary practices, through its wholly-owned subsidiary, Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare programme for pets branded "Premier Pet Care Plan" ("PPCP"). In the US, PPCP is marketed through the Company's wholly-owned subsidiary, Premier Vet Alliance (US) Limited.

 

PPCP is a structured, preventative healthcare programme for cats, dogs and rabbits and is available only through veterinary practices. The programme is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

 

PPCP uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed more quickly and not given a chance to advance. What truly sets PPCP apart is its unique approach of offering an end-to-end solution and support to the practice, which has been proven to work extremely well. PVA works alongside practices to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice performance.

 

For further details: http://www.premiervetalliance.co.uk/

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CNTUSOWRWBAWAAR
Date   Source Headline
2nd Jun 20154:55 pmRNSChange of Auditor
29th May 20157:00 amRNSHalf Yearly Report
7th May 20153:42 pmRNSChange of Registered Office
29th Apr 20157:01 amRNSTrading Statement
29th Apr 20157:00 amRNSFinal Results
13th Mar 201511:22 amRNSHolding(s) in Company
9th Mar 20157:00 amRNSRenamed Premier Veterinary Group
3rd Mar 201512:33 pmRNSHolding(s) in Company
3rd Mar 20159:48 amRNSHolding(s) in Company
2nd Mar 20152:36 pmRNSHolding(s) in Company
2nd Mar 201510:55 amRNSHolding(s) in Company
2nd Mar 201510:42 amRNSHolding(s) in Company
27th Feb 20154:35 pmRNSPrice Monitoring Extension
27th Feb 20154:07 pmRNSBoard Changes and Directors' Dealings
27th Feb 20158:00 amRNSCancellation
27th Feb 20157:00 amRNSAdmission to the Official List
26th Feb 20154:00 pmRNSCancellation and Publication of Prospectus
5th Feb 20154:22 pmRNSAcquisition completed
28th Jan 20159:29 amRNSSale and Purchase Agreement Signed
15th Jan 20157:00 amRNSTransfer of listing category on the Official List
4th Dec 201411:17 amRNSBlocklisting Interim Review
21st Nov 20145:48 pmRNSPosting of Circular
1st Aug 20147:00 amRNSHalf Yearly Report and Change of Registered Office
1st Jul 20147:00 amRNSResults of AGM and Board Changes
3rd Jun 20147:00 amRNSBlocklisting Interim Review
13th May 20147:00 amRNSInterim Management Statement
30th Apr 20147:00 amRNSFinal Results
28th Mar 20147:45 amRNSSuspension - Ark Therapeutics Group Plc
28th Mar 20147:32 amRNSSigned Heads of Terms and Suspension of Trading
25th Mar 201412:48 pmRNSHolding(s) in Company
4th Mar 201412:22 pmRNSHolding(s) in Company
21st Feb 20144:40 pmRNSSecond Price Monitoring Extn
21st Feb 20144:35 pmRNSPrice Monitoring Extension
20th Feb 201410:44 amRNSHolding(s) in Company
20th Feb 201410:39 amRNSHolding(s) in Company
20th Feb 201410:38 amRNSHolding(s) in Company
6th Dec 20135:46 pmRNSBlocklisting Interim Review
6th Nov 20137:00 amRNSInterim Management Statement
8th Oct 201311:27 amRNSHolding(s) in Company
7th Oct 20134:35 pmRNSPrice Monitoring Extension
7th Oct 20133:21 pmRNSHolding(s) in Company
27th Sep 201311:46 amRNSHolding(s) in Company
26th Sep 20133:26 pmRNSHolding(s) in Company
24th Sep 201311:02 amRNSHolding(s) in Company
20th Sep 201311:47 amRNSHolding(s) in Company
18th Sep 20134:40 pmRNSSecond Price Monitoring Extn
18th Sep 20134:35 pmRNSPrice Monitoring Extension
17th Sep 201310:00 amRNSHolding(s) in Company
13th Sep 201311:40 amRNSHolding(s) in Company
10th Sep 201310:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.